This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue.


You are about to leave a GSK website

Third party content disclaimers


You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independently operated and not managed by GSK. The website you are linking to is not controlled or endorsed by GSK and GSK assumes no responsibility for the content on the website. If you wish to proceed, click "OK". If you do not wish to leave this website, click “CANCEL”.



CI, confidence interval

Cardiovascular events, such as cardiac arrhythmias, may be seen after the administration of muscarinic recepter antagonists and sympatho-mimetic agents, including umeclidinium/vilanterol. Therefore, Anoro Ellipta should be used with caution in patients with severe cardiovascular disease. 2

Due to antimuscarinic activity (i.e. a LAMA class effect), Anoro Ellipta and Tiotropium/Olodaterol should be used with caution in patients with urinary retention or narrow angle glaucoma. 2 3

*Anoro showed superiority on the primary endpoint of trough FEV1 compared with Please change to Tiotropium/Olodaterol (5/5mcg)  3 with comparable safety profile (p<0.001) 1

**Trough FEV1 improved by 180mL for Anoro (n=225) vs. 128mL for Tiotropium/Olodaterol(n=224) at week 8, in the ITT population; difference 52mL (95% CI: 28, 77; p<0.001) 1

Reduced by 0.94 puffs/day for Anoro (n=222) vs. 0.68 puffs/day for Tiotropium/Olodaterol(n=217); difference in change from baseline with Anoro vs. Tiotropium/Olodaterol -0.25 (95% CI: -0.37, -0.14; p<0.001) 1

††Maintenance naïve: Patients who had not received a maintenance treatment (LAMA, LABA alone or in combination ± ICS) for COPD in the 30 days that records were kept prior to screening.

†††Post-hoc subgroup analysis at Week 8 in maintenance-naïve patients (n=148; 167mL vs. 110mL, Δ57mL; p=0.001)


  1. Feldman GJ, et al. Adv Ther. 2017;34:2518–2533
  2. Anoro Ellipta Prescribing Information, Malaysia. v04.
  3. Tiotropium/Olodaterol SmPC, 2017
  4. Feldman GJ et al. Adv Ther 2017; 34:2518-2533 (supplementary material).
  5. Alcazar Navarrete B. et al Pulm Ther. 2018

Trade marks are owned by or licensed to the GSK group of companies.